Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of NSCLC: focus on crizotinib.

Expert opinion on pharmacotherapy - 1 Dec 2014

Landi Lorenza, Cappuzzo Federico

Abstract excerpt

INTRODUCTION: Presence of Anaplastic lymphoma kinase (ALK) translocations identifies a distinct subgroup of NSCLC with different prognosis and therapeutic opportunities. In cancer cells, ALK gene fusion acts as oncogenic driver, representing an attractive therapeutic target in NSCLC. AREAS COVERED: For the purpose of this review article, data from preclinical and clinical trials with crizotinib were collected and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Clinical Trials as Topic
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 25301075
DOI: 10.1517/14656566.2014.970174

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of NSCLC: focus on crizotinib.PMID 25301075Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Semantic proximity Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisSemantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

Crizotinib: an anaplastic lymphoma kinase inhibitor.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Pharmacokinetics of crizotinib in NSCLC patients.Semantic proximity Read ↗

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Semantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Semantic proximity Read ↗

[Clinical research of crizotinib in advanced non-small cell lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.